{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:56:57Z","timestamp":1790261817418,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hana Nomura"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Moderate-to-severe atopic dermatitis (AD) affects the quality of life of patients. More treatment options are urgently needed to manage this chronic disease. Lebrikizumab is a monoclonal antibody that binds to interleukin-13, a key mediator in AD pathogenesis. In Japanese patients, lebrikizumab has been evaluated through week 16 in the randomized placebo-controlled phase III ADhere-J study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the long-term efficacy and safety of lebrikizumab in combination with topical corticosteroids (TCS) in the ADhere-J study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients aged \u226512\u2005years weighing \u2265 40\u2005kg with moderate-to-severe AD and receiving either subcutaneous lebrikizumab 250\u2005mg \u00adevery 2 weeks (Q2W)\/every 4 weeks (Q4W) or placebo during the 16-week induction period were evaluated during the long-term maintenance period from week 16 to week 68. Responders achieved the co-primary endpoints at week 16: an Investigator\u2019s Global Assessment score of 0 or 1 [IGA (0,1)] with \u2265 2-point improvement from baseline and\/or \u2265 75% improvement from baseline in Eczema Area and Severity Index (EASI 75). In this analysis, week 16 responders received lebrikizumab 250\u2005mg Q2W or Q4W combined with TCS during the maintenance period (maintenance primary population; MPP); week 16 per-protocol nonresponders received lebrikizumab Q2W with TCS (maintenance escape population; MEP). Major endpoints included IGA (0,1) with \u2265 2-point improvement from baseline and EASI 75 through week 68. Other outcomes included quality of life, itch and serum thymus and activation-regulated chemokine. The trial was registered with ClinicalTrials.gov (NCT04760314).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At week 68, 66\u201381% of 103 patients in the MPP and 32\u201338% of 168 patients in the MEP achieved IGA (0,1) with \u2265 2-point improvement from baseline. EASI 75 was maintained by 83\u201389% of patients in the MPP, while 71\u201380% of patients in the MEP achieved this outcome by week 68. Across treatment arms, patients in the MPP tended to maintain improvements recorded at week 16, while patients in the MEP steadily improved across the maintenance period. No new safety signals were reported, and most treatment-emergent adverse events were mild or moderate in severity in both populations. Safety outcomes were consistent with previous reports for lebrikizumab treatment in global studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These results support the use of lebrikizumab in combination with TCS for the treatment of moderate-to-severe AD in the Japanese population in the long term.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljae394","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T19:37:03Z","timestamp":1729712223000},"page":"597-610","source":"Crossref","is-referenced-by-count":9,"title":["Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week randomized double-blind placebo-controlled phase III trial in Japan (ADhere-J)"],"prefix":"10.1093","volume":"192","author":[{"given":"Norito","family":"Katoh","sequence":"first","affiliation":[{"name":"Department of Dermatology, Kyoto Prefectural University of Medicine , Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University , Hiroshima ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Takagi Dermatological Clinic , Hokkaido ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Shimizu Dermatology Clinic , Kobe ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Osaka Habikino Medical Center , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoe","family":"Torisu-Itakura","sequence":"additional","affiliation":[{"name":"Eli Lilly Japan K.K. , Kobe ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Morisaki","sequence":"additional","affiliation":[{"name":"Eli Lilly Japan K.K. , Kobe ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Eli Lilly Japan K.K. , Kobe ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Igawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Dokkyo Medical University , Shimotsuga-gun, Tochigi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"2025031819362100300_ljae394-B1","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.alit.2022.06.009","article-title":"Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021","volume":"71","author":"Saeki","year":"2022","journal-title":"Allergol Int"},{"key":"2025031819362100300_ljae394-B2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/bjd.21615","article-title":"The Validated Investigator Global Assessment for atopic dermatitis (vIGA-AD\u2122): a clinical outcome measure for the severity of atopic dermatitis","volume":"187","author":"Simpson","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025031819362100300_ljae394-B3","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1080\/13696998.2021.2002559","article-title":"Evaluating the burden of pruritus due to atopic dermatitis in Japan by patient-reported outcomes","volume":"24","author":"Murota","year":"2021","journal-title":"J Med Econ"},{"key":"2025031819362100300_ljae394-B4","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jaad.2022.01.009","article-title":"American Academy of Dermatology Guidelines: awareness of comorbidities associated with atopic dermatitis in adults","volume":"86","author":"Davis","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025031819362100300_ljae394-B5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.anai.2020.08.016","article-title":"New treatments in atopic dermatitis","volume":"126","author":"Puar","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025031819362100300_ljae394-B6","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/1346-8138.16549","article-title":"The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan","volume":"49","author":"Hagino","year":"2022","journal-title":"J Dermatol"},{"key":"2025031819362100300_ljae394-B7","doi-asserted-by":"crossref","first-page":"100195","DOI":"10.1016\/j.xjidi.2023.100195","article-title":"Optimal use of Jak inhibitors and biologics for atopic dermatitis on the basis of the current evidence","volume":"3","author":"Kamata","year":"2023","journal-title":"JID Innov"},{"key":"2025031819362100300_ljae394-B8","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s13555-022-00751-9","article-title":"Difamilast ointment in Japanese adult and pediatric patients with atopic dermatitis: a phase III, long-term, open-label study","volume":"12","author":"Saeki","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025031819362100300_ljae394-B9","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2025031819362100300_ljae394-B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/03007995.2024.2436982","article-title":"Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J)","author":"Katoh","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"2025031819362100300_ljae394-B11","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/bjd\/ljad022","article-title":"Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials","volume":"188","author":"Blauvelt","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025031819362100300_ljae394-B12","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/exd.13911","article-title":"Understanding the immune landscape in atopic dermatitis: the era of biologics and emerging therapeutic approaches","volume":"28","author":"Moyle","year":"2019","journal-title":"Exp Dermatol"},{"key":"2025031819362100300_ljae394-B13","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/jamadermatol.2022.5534","article-title":"Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere)","volume":"159","author":"Simpson","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2025031819362100300_ljae394-B14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","article-title":"The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group","volume":"10","author":"Hanifin","year":"2001","journal-title":"Exp Dermatol"},{"key":"2025031819362100300_ljae394-B15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/bjd.14464","article-title":"Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Kimball","year":"2016","journal-title":"Br J Dermatol"},{"key":"2025031819362100300_ljae394-B16","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.jid.2019.03.1152","article-title":"Validation and interpretation of Short Form 12 and comparison with Dermatology Life Quality Index in atopic dermatitis in adults","volume":"139","author":"Silverberg","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2025031819362100300_ljae394-B17","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jaci.2003.12.007","article-title":"Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis","volume":"113","author":"Hijnen","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"2025031819362100300_ljae394-B18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/1346-8138.12440","article-title":"Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis","volume":"41","author":"Kataoka","year":"2014","journal-title":"J Dermatol"},{"key":"2025031819362100300_ljae394-B19","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaad.2020.05.052","article-title":"The role of thymus and activation-regulated chemokine as a marker of severity of atopic dermatitis","volume":"84","author":"Himadri","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2025031819362100300_ljae394-B20","doi-asserted-by":"crossref","first-page":"1091271","DOI":"10.3389\/fmed.2022.1091271","article-title":"The efficacy and safety of lebrikizumab monotherapy for the management of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis","volume":"9","author":"Bashrahil","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2025031819362100300_ljae394-B21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/JAA.S211032","article-title":"Therapeutic potential of lebrikizumab in the treatment of atopic dermatitis","volume":"13","author":"Loh","year":"2020","journal-title":"J Asthma Allergy"},{"key":"2025031819362100300_ljae394-B22","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s13555-023-00942-y","article-title":"Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: a 52-week, open-label, phase 3 study","volume":"13","author":"Paller","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025031819362100300_ljae394-B23","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaci.2022.11.023","article-title":"Skin TARC\/CCL17 increase precedes the development of childhood atopic dermatitis","volume":"151","author":"Halling","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"2025031819362100300_ljae394-B24","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N Engl J Med"},{"key":"2025031819362100300_ljae394-B25","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1136\/annrheumdis-2015-207841","article-title":"Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance","volume":"74","author":"Winthrop","year":"2015","journal-title":"Ann Rheum Dis"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae394\/60011492\/ljae394.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/4\/597\/60011492\/ljae394.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/4\/597\/60011492\/ljae394.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T19:36:40Z","timestamp":1742326600000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/192\/4\/597\/7833478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,10,23]]},"published-print":{"date-parts":[[2025,3,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae394","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,10,23]]}}}